Inhibition of agonist-induced down-regulation of the δ-opioid receptor with a proteasome inhibitor attenuates opioid tolerance in human embryonic kidney 293 cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 3, 2007, Pages 1186-1194

  Yadav, Prem N ^a   Chaturvedi, Kirti ^a,b   Howells, Richard D ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DELTA OPIATE RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; EPITOPE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MITOGEN ACTIVATED PROTEIN KINASE; OPIATE AGONIST; PROTEASOME INHIBITOR; RECEPTOR PROTEIN;

ARTICLE; BINDING SITE; CELL MEMBRANE; CELL STRAIN HEK293; CONTROLLED STUDY; DOWN REGULATION; DRUG TOLERANCE; EMBRYO; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BINDING SITES; CELL LINE; CELL MEMBRANE; DOWN-REGULATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENKEPHALIN, LEUCINE-2-ALANINE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; KIDNEY; LEUPEPTINS; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, DELTA; TRANSFECTION;

EID: 33847124520     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.113621     Document Type: Article

References (40)

1. Arttamangkul S, Torrecilla M, Kobayashi K, Okano H, and Williams JT (2006) Separation of μ-opioid receptor desensitization and internalization: endogenous receptors in primary neuronal cultures. J Neurosci 26:4118-4125.
2. Bailey CP and Connor M (2005) Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 5:60-68.
3. Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim J-H, Lund S, Na H-M, Taylor G, Bence NF, et al. (2006) Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin-proteasome system. Neurobiol Disease 22: 404-420.
4. Bohn LM, Gainetdinov RR, Lin F-T, Lefkowitz RJ, and Caron MG (2000) μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence. Nature (Lond) 408:720-723.
5. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, and Lin F-T (1999) Enhanced morphine analgesia in mice lacking β-arrestin-2. Science (Wash DC) 286:2495-2498.
6. Breivogel CS, Selley DE, and Childers SR (1997) Acute and chronic effects of opioids on δ and μ receptor activation of G proteins in NG108-15 and SK-N-SH cell membranes. J Neurochem 68:1462-1472.
7. Broom DC, Nitsche JF, Pintar JE, Rice KC, Woods JH, and Traynor JR (2002) Comparison of receptor mechanisms and efficacy requirements for δ-agonist-induced convulsive activity and antinociception in mice. J Pharmacol Exp Ther 303:723-729.
8. Chaturvedi K, Bandari P, Chinen N, and Howells RD (2001) Proteasome involvement in agonist-induced down-regulation of mu and delta opioid receptors. J Biol Chem 276:12345-12355.
9. Chaturvedi K, Jiang X, Christoffers KH, Chinen N, Bandari P, Raveglia LF, Ronzoni S, Dondio G, and Howells RD (2000) Pharmacological profiles of selective nonpeptidic delta opioid receptor ligands. Mol Brain Res 80:166-176.
10. Chu P, Murray S, Lissin D, and von Zastrow M (1997) Delta and kappa opioid receptors are differentially regulated by dynamin-dependent endocytosis when activated by the same alkaloid agonist. J Biol Chem 272:27124-27130.
11. Cotrell GS, Padilla B, Pikios S, Roosterman D, Steinhoff M, Gehringer D, Grady EF, and Bunnett NW (2006) Ubiquitin-dependent down-regulation of the neurokinin-1 receptor. J Biol Chem 281:2777-2778.
12. Fernandes AZ, Cherla RP, Chernock RD, and Ganju RK (2002) CXCR4/CCR5 downmodulation and chemotaxis are regulated by the proteasomal pathway. J Biol Chem 277:18111-18117.
13. Hershko A, Ciechanover A, and Varshavsky A (2000) The ubiquitin system. Nat Med 6:1073-1081.
14. Howells RD, Chaturvedi K, Bandari P, and Chinen N (1999) Degradation of opioid receptors by the proteasome. Dolor 14 (Suppl 1):24.
15. Jacob C, Cotrell GS, Gehringer D, Schmidlin F, Grady EF, and Bunnett NW (2005) cCbl mediates ubiquitination, degradation, and down-regulation of human protease-activated receptor 2. J Biol Chem 280:16076-16087.
16. Joazeiro CAP, Anderson KC, and Hunter T (2006) Proteasome inhibitor drugs on the rise. Cancer Res 66:7840-7842.
17. Johansson BB, Minsaas L, and Aragay AM (2005) Proteasome involvement in the degradation of the G(q) family of G alpha subunits. FEBS J 272:5365-5377.
18. Jutkiewicz EM, Kaminsky ST, Rice KC, Traynor JR, and Woods JH (2005) Differential behavioral tolerance to the δ-opioid agonist SNC80 ([(+)-4-[(αR)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl] -(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats. J Pharmacol Exp Ther 315:414-422.
19. Kisselev AF and Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8:739-758.
20. Law PY, Hom DS, and Loh HH (1983) Opiate receptor down-regulation and desensitization in neuroblastoma x glioma NG108-15 hybrid cells are two separate cellular adaption processes. Mol Pharmacol 24:413-424.
21. Law PY, McGinn TM, Wick MJ, Erikson LJ, Evans C, and Loh HH (1994) Analysis of delta-opioid receptor activities stably expressed in CHO cell lines: function of receptor density? J Pharmacol Exp Ther 271:1686-1694.
22. Lefkowitz RJ and Shenoy SK (2005) Transduction of receptor signals by β-arrestins. Science (Wash DC) 308:512-517.
23. Li JG, Benovic JL, and Liu-Chen LY (2000) Mechanisms of agonist-induced downregulation of the human kappa opioid receptor: internalization is required for down-regulation. Mol Pharmacol 58:795-801.
24. Marchese A and Benovic JL (2001) Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting. J Biol Chem 276:45509-45512.
25. McQuay H (1999) Opioids in pain management. Lancet 353:2229-2232.
26. Mouledous L, Neasta J, Uttenweller-Joseph S, Stella A, Matondo M, Corbani M, Monserrat B, and Meunier JC (2005) Long-term morphine treatment enhances proteasome-dependent degradation of Gβ in human neuroblastoma SH-SY5Y cells: correlation with onset of adenylate cyclase sensitization. Mol Pharmacol 68:467-476.
27. Obin MS, Jahngen-Hodge J, Nowell T, and Taylor A (1996) Ubiquitinylation and ubiquitin-dependent proteolysis in vertebrate photoreceptors (rod outer segments). J Biol Chem 271:14473-14484.
28. Okura T, Varga EV, Hosohata Y, Navratilova E, Cowell SM, Rice K, Nagase H, Hruby VJ, Roeske WR, and Yamamura HI (2003) Agonist-specific down-regulation of the human δ-opioid receptor. Eur J Pharmacol 459:9-16.
29. Pei G, Kieffer BL, Lefkowitz RJ, and Freedman NJ (1995) Agonist-dependent phosphorylation of the mouse delta-opioid receptor: involvement of G protein-coupled receptor kinases but not protein kinase C. Mol Pharmacol 48:173-177.
30. Petaja-Repo UE, Hogue M, Laperriere A, Bhalla S, Walker P, and Bouvier M (2001) Newly synthesized human δ opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated and degraded by the proteasome. J Biol Chem 276:4416-4423.
31. Pineyro G, Azzi M, deLean A, Schiller PW, and Bouvier M (2005) Reciprocal regulation of agonist and inverse agonist signaling efficacy upon short-term treatment of the human δ-opioid receptor with an inverse agonist. Mol Pharmacol 67:336-348.
32. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, and Bennink JR (2000) Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature (Lond) 404:770-774.
33. Shenoy SK, McDonald PK, Kohout TA, and Lefkowitz RJ (2001) Regulation of receptor fate by ubiquitination of activated β2-adrenergic receptor and β-arrestin. Science (Wash DC) 294:1307-1313.
34. Sittl R, Nuijten M, and Poulsen Nautrup B (2005) Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and non-cancer pain in Germany: results of a retrospective cohort study. Clin Ther 27:1022-1031.
35. 5]enkephalin treatment. Brain Res 462:313-320.
36. Tsao PI and von Zastrow M (2000) Type-specific sorting of G protein-coupled receptors after endocytosis. J Biol Chem 275:11130-11140.
37. Tseng LF, Narita M, Mizoguchi H, Kawai K, Mizusuna A, Kamei J, Suzuki T, and Nagase H (1997) Delta-1 opioid receptor-mediated antinociceptive properties of a nonpeptidic delta opioid receptor agonist, (-)TAN-67, in the mouse spinal cord. J Pharmacol Exp Ther 280:600-605.
38. Tsubuki S, Saito Y, Tomioka M, Ito H, and Kawashima S (1996) Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem 199:572-576.
39. Xu H, Wang X, Zimmerman D, Boja ES, Wang J, Bilsky EJ, and Rothman RB (2005) Chronic morphine up-regulates Gα12 and cytoskeletal proteins in Chinese hamster ovary cells expressing the cloned μ opioid receptor. J Pharmacol Exp Ther 315:248-255.
40. 4]deltorphin II on tolerance to their analgesic action and on brain δ-opioid receptors. Brain Res 745:243-247.